Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04619056
Recruitment Status : Recruiting
First Posted : November 6, 2020
Last Update Posted : March 9, 2022
Sponsor:
Information provided by (Responsible Party):
CEBIOTEX

Brief Summary:

This is an open label, first-in-man clinical trial to assess safety and tolerability of CEB-01 PLGA membrane in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma after surgery.

The trial will be conducted in 3 dose-escalation cohorts (3 patients each, enrolling patients one by one, after 4 weeks of observation and agreement of Scientific Committee and DMC) and in an expansion cohort, using the highest safe and tolerable dose. The study will follow a 3+3 modified design; dose escalation will follow a modified Fibonacci method. CEB-01 carrying a SN-38 dose between 9 and 36 mg will be placed in the surgical bed at the time of tumor resection.


Condition or disease Intervention/treatment Phase
Locally Advanced Soft Tissue Sarcoma Recurrent Soft Tissue Sarcoma Combination Product: CEB-01 membrane loaded with SN-38 Phase 1

Detailed Description:

CEB-01 is a poly(lactic-co-glycolic acid) (PLGA) polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.

CEB-01 carrying a SN-38 dose between 9 and 36 mg will be administered. CEB-01 will be placed on all surfaces that were in contact with and/or were infiltrated by the tumor.

Confirmatory central reviewing of diagnosis will be performed for all patients, using tumor samples obtained during surgery; additionally, patients will also be included according to local Pathological Anatomy (PA) diagnosis.

Patients will be followed-up once every week during the first 8 weeks of the study, and then every 2 weeks up to 12 weeks after implantation of CEB-01. Thereafter, follow-up schedule will be as per normal practice until study completion.

Efficacy assessment will be performed by Magnetic Resonance Imaging (MRI) [Computed tomography (CT) scan and Positron Emission Tomography (PET-CT) are also allowed] according to RECIST 1.1 criteria. Baseline image determination will be performed at week 12 (±3 days) after surgery; if the image analysis is not conclusive due to wound healing in the tumor bed, it will be repeated on week 16 (±3 days) post-surgery, and every 12 weeks thereafter.

A pharmacokinetic assessment of SN-38 will be performed in all patients, and the Cmax, Tmax, half-life, and area under the time-drug concentration curve (AUC) of the drug will be determined. Blood samples will be collected at baseline and at 8 time points after CEB-01 implantation.

Assessment of adverse events, safety, and toxicity will be performed according to the Common Terminology Criteria for Adverse Events (CTCAE - version 5.0) at each patient visit from the time of Informed Consent until the end of the study.

Quality of Life based on EORTC Quality of Life Questionnaire (QLQ) 30 will be measured prior surgery, at month 1 and month 3.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

This is an open label, first-in-man clinical trial that will be conducted in 3 dose-escalation cohorts (3-6 patients each) and in an expansion cohort, at the highest dose determined to be safe and tolerable.

CEB-01 loaded with a SN-38 dose between 9 and 36 mg will be allocated to each patient.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: First-in-man Clinical Trial to Assess Safety and Tolerability of CEB-01 PLGA Membrane in Patients With Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma After Surgery
Actual Study Start Date : June 3, 2020
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : April 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort 1
CEB-01 with total SN-38 dose: 9 mg
Combination Product: CEB-01 membrane loaded with SN-38
CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.

Experimental: Cohort 2
CEB-01 with total SN-38 dose: 18 mg
Combination Product: CEB-01 membrane loaded with SN-38
CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.

Experimental: Cohort 3
CEB-01 with total SN-38 dose: 36 mg
Combination Product: CEB-01 membrane loaded with SN-38
CEB-01 is a polymeric drug with a delivery system loaded with SN-38, and will be placed in the surgical bed at the time of tumor resection.




Primary Outcome Measures :
  1. Recommended Doses for Phase II (Maximum tolerated dose) [ Time Frame: Through 2 weeks ]
    The number of patients experiencing dose limiting toxicities during the Dose Limiting Toxicities (DLT) observation period of 2 weeks.


Secondary Outcome Measures :
  1. Frequency of Adverse Events (AEs) (Safety) [ Time Frame: Through study completion, average 2 years ]
    Frequency of adverse events reported classified by type and severity.

  2. Frequency of Treatment Related Adverse Events (TRAEs) (Toxicity) [ Time Frame: Through study completion, average 2 years ]
    Frequency of treatment related adverse events reported classified by type and severity.

  3. Time to local relapse (TTLR) [ Time Frame: Through study completion, average 2 years ]

    Time from the start of treatment to the date of local relapse according to the RECIST 1.1 criteria, or death due to any cause. Those patients who are alive and have not relapsed at the last follow-up, will be censored at the date of the last follow-up.

    Relapse definition: For patients in which R0 is obtained by surgery, relapsed should be considered when disease reappears with size > 1 cm (measurable disease). For patients with R1 or R2, RECIST 1.1 guideline should be used for disease progression definition.


  4. Progression Free Survival (PFS) [ Time Frame: Through study completion, average 2 years ]
    Time from the start of treatment to the date of the first progression according to the RECIST 1.1 criteria, or death due to any cause. Those patients who are alive and have not progressed at the last follow-up, date of progression will be censored at the date of the last follow-up.

  5. Overall Survival (OS)(until 24 months of Follow Up (FU)) [ Time Frame: Through study completion, average 2 years ]
    Median of overall survival. Time from the start of the trial treatment to the date of exitus for any cause. In those patients who are alive at the last follow-up, OS will be censored by the date of the last follow-up in which the patient was alive.

  6. Quality of life: EORTC QLQ 30 [ Time Frame: Prior to surgery, at month 1 and month 3 after surgery ]
    Questionnaire developed and validated to assess the quality of life of cancer patients.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age >18 years.
  2. Histologically confirmed diagnosis of locally advanced (T3 -T4, American Joint Committee on Cancer (AJCC)/primary tumor, regional lymph nodes, and distant metastases staging system (TMN) 8th Edition) and/or relapsed (any) retroperitoneal soft tissue sarcoma (liposarcoma, leiomyosarcoma, a solitary fibrous tumor (SFT), pleomorphic sarcoma, or a malignant nerve sheath tumor). Patients with local advanced (T3 -T4,AJCC/TMN 8th Edition) and/or relapse and metastatic disease who are candidates for local surgery without option of systemic treatment, are also eligible for the trial.
  3. Pathology specimens available for centralized review. Submission of formalin-fixed paraffin-embedded (FFPE) tumor tissue for central reviewing is required; if a FFPE block cannot be provided, then 10 unstained, positively-charged slides of 4-5 um thickness must be submitted.
  4. Size of tumor (visible or previously inadequately resected) >5 cm at instrumental staging (CT, MRI).
  5. Normal liver, renal, hematological, and cardiac function as defined by biochemical and hematological parameters as follows: Hb >11 g/dL, platelets >100.000/mm3, White Blood Cells (WBC) >3000/mm3, neutrophil count >1500/mm3, albumin >3.0 g/dl, Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) <2.5 times the upper limit of normality (ULN), bilirubin <2 times the ULN, creatinine <1.5 mg/dl or creatinine clearance > 60 ml/min.
  6. Eastern Cooperative Oncology Group (ECOG) Performance Status <2.
  7. No concomitant radiotherapy or chemotherapy planned.
  8. Life expectancy greater than 6 months.
  9. Female subjects of childbearing potential must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening.
  10. Men and women of childbearing potential must be willing to use adequate contraception throughout the study and for 3 months after surgery.
  11. Ability to understand and the willingness to sign a written informed consent document; subject has signed an Informed Consent Form (ICF) prior to any screening procedures and is able to comply with protocol requirements.

Exclusion Criteria:

  1. Pregnancy or lactation. Note: Pregnant women are excluded from this study; if the patient is a lactating mother, breastfeeding should be discontinued.
  2. Other malignancies within past 5 years, with the exception of carcinoma in situ of cervix and basocellular skin cancers treated with eradicating intent.
  3. Serious psychiatric disease that precludes informed consent or limits compliance
  4. Medical condition limiting survival to less than 6 months.
  5. Uncontrolled bacterial, viral or fungal infection.
  6. Active viral hepatitis or chronic liver disease.
  7. Impossibility of ensuring adequate follow-up.
  8. Contraindication to magnetic resonance imaging (MRI), including presence of a pacemaker or an aneurysm clip, severe claustrophobia, a known reaction to the gadolinium contrast dye, or body weight that could interfere with the feasibility of a MRI.
  9. Major surgery within 14 days prior to starting study drug or still in recovery after experiencing surgical complications; neither tumor biopsy nor central line insertion are considered a major surgery.
  10. Unable or unwilling to stop the use of herbal supplements; the use of nutritional supplements may be allowed after review by a study pharmacist to confirm no significant risk of interaction with eribulin or radiation.
  11. Other relevant concomitant illnesses.
  12. Patients previously treated with Irinotecan.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04619056


Contacts
Layout table for location contacts
Contact: A responsible person designated by the sponsor 0034934344412 ext 102 investigacion@mfar.net

Locations
Layout table for location information
Spain
Hospital de la Santa Creu i Sant Pau Recruiting
Barcelona, Cataluña, Spain, 08041
Contact: A responsible person designated by the sponsor    0034934344412 ext 102    investigacion@mfar.net   
Principal Investigator: Antonio López Pousa, M.D. P.hD.         
Hospital Universitario Vall d'Hebron Recruiting
Barcelona, Spain, 08035
Contact: A responsible person designated by the sponsor    003493434412 ext 102    investigacion@mfar.net   
Principal Investigator: Principal investigator selected by the sponsor, M.D. PhD         
Hospital General Universitario Gregorio Marañón Recruiting
Madrid, Spain, 28007
Contact: A responsible person designated by the sponsor    003493434412 ext 102    investigacion@mfar.net   
Principal Investigator: Principal investigator selected by the sponsor, MD. P.hD.         
Fundación Jiménez Díaz Recruiting
Madrid, Spain, 28040
Contact: A responsible person designated by the sponsor    003493434412 ext 102    investigacion@mfar.net   
Principal Investigator: Principal investigator selected by the sponsor, M.D. PhD         
Hospital Universitario y Politécnico La Fe Recruiting
Valencia, Spain, 46026
Contact: A responsible person designated by the sponsor    0034934344412 ext 102    investigacion@mfar.net   
Principal Investigator: Principal investigator selected by the sponsor, M.D P.hD.         
Sponsors and Collaborators
CEBIOTEX
Investigators
Layout table for investigator information
Study Chair: Antonio López Pousa, M.D. Ph.D. Hospital Universitari de la Santa Creu i Sant Pau
Layout table for additonal information
Responsible Party: CEBIOTEX
ClinicalTrials.gov Identifier: NCT04619056    
Other Study ID Numbers: CEB-01-RLS01-CT
2018-001026-25 ( EudraCT Number )
First Posted: November 6, 2020    Key Record Dates
Last Update Posted: March 9, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CEBIOTEX:
Soft tissue sarcoma
Retroperitoneal
Recurrent or locally advanced
CEB-01 PLGA membrane
SN-38
Local drug delivery system
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcoma
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms